SCHEMBL12848502

SCHEMBL12848502

CCOc1cc(-c2cn3ccccc3n2)ccc1OCc1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 12/20 0.58
▸ NPC1 O15118 11/20 0.58
▸ SMN1; SMN2 Q16637 9/20 0.58
▸ ALDH1A1 P00352 9/20 0.58
▸ MAPT P10636 5/20 0.58
▸ PKM P14618 4/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ KDM4E B2RXH2 7/20 0.55
▸ HPGD P15428 4/20 0.55
▸ TSHR P16473 2/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ TP53 P04637 1/20 0.55
▸ LMNA P02545 1/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ ATM Q13315 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ TACR2 P21452 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12848886 0.92 RAB9A (0.62) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6527793 0.91 RAB9A (0.68) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL12797255 0.88 HRH3 (0.59) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL12797418 0.86 RAB9A (0.62) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL12797427 0.85 RAB9A (0.58) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL9284193 0.82 RAB9A (0.74) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6388711 0.82 RAB9A (0.74) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL12848499 0.81 NPC1 (0.69) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL12848976 0.81 RAB9A (0.69) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL12848876 0.81 RAB9A (0.65) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895599-B2 Lipoprotein lipase-activating compositions comprising benzene derivates OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2014-11-25 — — US disclosed
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2013-11-07 — — US disclosed
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES LPL, LIPC, LIPE RAB9A 3933/4885NPC1 366/4885SMN1; SMN2 4449/4885
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES LPL, LIPC, LIPE RAB9A 3849/4885NPC1 334/4885SMN1; SMN2 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback